GlassScriptPhysician profile
Marianne D Moses
NPI 1225317290
$7,144.32
in general payments reported to CMS, 2019-2025
27 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $513 · 2023: $1,619 · 2024: $2,268 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,049 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,049.01 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.65 | 2022-2025 | |
| Novo Nordisk INC | $901.39 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $706.56 | 2023-2025 | Fasenra, Tezspire, Farxiga |
| Daiichi Sankyo INC. | $599.54 | 2023-2025 | Injectafer |
| Lilly USA, LLC | $394.89 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.78 | 2021-2025 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $307.69 | 2024-2025 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $263.20 | 2021-2025 | |
| Medtronic, INC. | $256.19 | 2023-2024 | Venaseal, Minimed 780g |
| Amgen INC. | $247.63 | 2024-2025 | Evenity, Repatha, Otezla |
| Exact Sciences Corporation | $199.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $176.18 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.58 | 2021-2024 | Jardiance |
| Pfizer INC. | $144.26 | 2025 | |
| Edwards Lifesciences Corporation | $136.20 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $121.84 | 2023 | Apretude |
| Phathom Pharmaceuticals, INC. | $114.48 | 2025 | Voquezna |
| Corcept Therapeutics | $104.63 | 2025 | Korlym |
| Optinose US, INC. | $97.93 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $96.88 | 2024 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $95.58 | 2023 | Epclusa |
| Abbott Laboratories | $93.50 | 2025 | Jot Dx |
| Alk-Abello, INC | $91.28 | 2024-2025 | Odactra, Grastek |
| Braeburn INC. | $86.60 | 2025 | Brixadi |
| Nestle Healthcare Nutrition INC. | $56.69 | 2023 | |
| Agios Pharmaceuticals, INC. | $23.63 | 2024 | |
| Hologic Sales and Service, LLC | $22.94 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marianne Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.